Written By
Edited By : Renée Deveney
Legally Reviewed By : Jonathan M. Sedgh, Esquire
This page features 24 Cited Research Articles
Fact Checked
Legally Reviewed

Consumer Notice, LLC content is legally reviewed for accuracy and quality.

Examples of trusted legal reviewers include qualified mass torts lawyers and certified paralegals.

Consumer Notice, LLC writers gather lawsuit information by studying court records, watching lawsuit proceedings and speaking with experienced attorneys.

Latest Ozempic Lawsuit Updates

Ozempic manufacturer Novo Nordisk faces multiple lawsuits alleging patients developed serious side effects. These include gastroparesis, severe vomiting and intestinal blockages after taking the drug.

In February 2024, a federal panel consolidated 55 Ozempic and related lawsuits into multidistrict litigation (MDL) in the Eastern District of Pennsylvania. A multi-district litigation groups similar cases under one court, which helps expedite the legal process. The Ozempic lawsuits include other drugs in the GLP-1 receptor agonist class.

As of March 2025, 1,521 cases were pending in the MDL.

Status of Ozempic Lawsuits
  • December 2024
    For this year, the FDA’s Adverse Event Reporting System showed over 52,000 complications reported to the agency.
  • November 2024
    Since Sept. 3, 2024, the number of cases in the multidistrict litigation grew by 40% — from 869 to 1,221. This indicates a surge of GLP-1 lawsuits.
  • July 2024
    Lawyers are investigating lawsuits related to vision loss and blindness linked to Ozempic. This comes after researchers published a 2024 study in JAMA Ophthalmology. The study reported that patients who took semaglutide-containing drugs had an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION). This incurable eye condition causes vision loss.
  • May 2024
    U.S. District Judge Gene E. K. Pratter, who presided over the MDL, passed away unexpectedly on May 17. Attorneys expected delays while the case was reassigned.
  • February 2024
    The U.S. Judicial Panel on Multidistrict Litigation combines 55 lawsuits claiming injuries from GLP-1 RAS class diabetes and weight-loss drugs into an MDL. The medicines named in lawsuits include Novo Nordisk's Ozempic, Wegovy and Rybelsus, and Eli Lilly's Trulicity and Mounjaro.
  • November 2023
    They claim that Novo Nordisk did not properly warn potential patients about Ozempic’s link with gastroparesis.
  • September 2023
    The FDA added ileus, a type of intestinal obstruction, to Ozempic’s prescribing information.
  • August 2023
    Jaclyn Bjorklund files one of the first lawsuits citing gastroparesis.
  • March 2022
    A study in JAMA Internal Medicine found higher doses and longer use of Ozempic and other GLP-1 RAs were associated with higher risks of gallbladder and biliary disease. This disease affects the gallbladder, bile ducts and liver. Novo Nordisk also filed patent infringement lawsuits against Sun Pharmaceutical Industries and Mylan in Delaware.
  • December 2021
    This year, over 4,000 people reported serious side effects from Ozempic and other semaglutide drugs. These complaints included stomach paralysis and gallbladder issues.

Patients are filing against Ozempic’s manufacturer, Novo Nordisk. Subsequently, Nordisk filed 12 suits against spas, weight loss clinics and compounding pharmacies. The company says it acted to protect patients from illegal semaglutide sales for uses that are not FDA-approved.

Why Are People Filling Ozempic Lawsuits?

People who took Ozempic for weight loss or Type 2 diabetes are filing lawsuits after experiencing adverse reactions, such as gastroparesis, severe vomiting or ileus, while taking Ozempic or shortly after stopping the drug.

The multidistrict litigation primarily involves severe gastrointestinal issues, especially gastroparesis. This condition causes delayed gastric emptying and significant symptoms.

Additionally, some claim serious injuries such as vision loss, including NAION, and risks of blood clots like deep vein thrombosis (DVT) and pulmonary embolism (PE). Some plaintiffs have experienced suicidal thoughts related to the medications.

Plaintiffs claim the manufacturer failed to warn doctors and patients about these severe risks and side effects.

“Defendants spent $884,000,000 on running television ads in the United States to promote its semaglutide drugs … but it does not disclose the risk of gastroparesis.”

Lawsuits Claim Ozempic Side Effects Included Gastroparesis and Ileus

Gastroparesis is when the stomach fails to empty because the muscles either slow down or stop working altogether. Symptoms include nausea, vomiting, bloating, abdominal pain, acid reflux, weight loss and loss of appetite. Currently, there is no cure for stomach paralysis, but treatments offer temporary benefits.

Similar to gastroparesis, ileus affects a person’s ability to digest food. Symptoms include bloating, abdominal cramps, nausea, constipation, vomiting, difficulty passing gas and difficulty tolerating a regular diet.

Lawyers Investigating Ozempic Vision Loss Lawsuits

A 2024 study published in JAMA Ophthalmology found an association between semaglutide and nonarteritic anterior ischemic optic neuropathy (NAION), a condition that causes vision loss. It typically affects only one eye, though around 15% of people with NAION will eventually develop the condition in their other eye, too. It may cause vision loss severe enough to classify as legally blind.

Lawyers began investigating potential Ozempic vision loss and blindness claims.

Compared with patients not on a GLP-1 agonist, those with obesity who took semaglutide for weight loss had over a sevenfold higher risk of developing NAION. People with Type 2 diabetes who take semaglutide have a fourfold higher risk.

NAION occurs when blood flow to the optic nerve stops, and there is no cure. Researchers think that GLP-1 drugs could affect the optic nerve, leading to the development of the eye condition.

Who Qualifies for an Ozempic Lawsuit?

Patients may qualify to file an Ozempic lawsuit if they have experienced stomach paralysis or severe vomiting for four weeks or more, suffered an intestinal blockage or received a diagnosis of ileus after taking Ozempic.

Generally, lawyers do not take cases for people who had gastric bypass, gastric banding or gastric sleeve surgery. If you are being treated for cancer, you may not qualify. Only a licensed Ozempic lawyer can tell you if you are eligible, so contact an attorney to see if you have a case.

Expert legal counsel can help you determine if pursuing a lawsuit is right for you. Lawsuits can help people receive compensation to help cover medical expenses and lost wages.

Case Study: Severe Gastroparesis With Ozempic and Mounjaro Use

Falisha Teague, a 34-year-old from Manchester, Kentucky, was looking for help with her Type 2 diabetes. She started using Ozempic and later Mounjaro, both designed to help control blood sugar levels. From March to December 2023, she used these injections regularly.

While these medications are often promoted as helpful for managing diabetes, they can have detrimental side effects. Teague developed a serious condition called gastroparesis, which means her stomach struggles to empty properly.

This condition has greatly affected her daily life and overall well-being.

Teague experienced debilitating symptoms associated with gastroparesis, including persistent nausea, severe vomiting of undigested food and unrelenting abdominal pain. These symptoms led to severe dehydration and multiple emergency department visits.

Additional complications included weight loss, malnutrition and chronic acid reflux.

The gastroparesis diagnosis dramatically altered Teague’s life, according to the complaint she filed in an Ozempic lawsuit. She now faces the challenge of managing a chronic condition without a cure. Her attorneys say she depends on medical help to ease her symptoms but also has to handle the costs of these treatments.

three icons representing filing a lawsuit
Did you or a loved one suffer from severe gastroparesis, ileus or intestinal obstruction after taking Ozempic?
Get your free case review today.

How To File an Ozempic Lawsuit

To file an Ozempic lawsuit, first, contact an experienced product liability attorney. It’s important to choose one who specializes in pharmaceutical cases. A skilled attorney can guide you through filing and litigating your case.

For example, Consumer Notice works with the national award-winning law firm Morgan & Morgan. The firm filed the first Ozempic lawsuit on behalf of Jaclyn Bjorklund. Bjorklund suffered from severe vomiting and gastroparesis after taking Ozempic. The vomiting caused her teeth to fall out and led to several hospitalizations.

Steps for Filing an Ozempic Lawsuit
  1. Consult a lawyer with a record of success working with drug injury cases.
  2. Gather the necessary documentation to support your claim, particularly your medical records. The law firm may be able to help.
  3. Be sure to work with a lawyer you feel comfortable with. This lawyer should offer clear, consistent communication. Your lawyer can discuss the case with you and explain the process.
  4. Your discussions and documents can help your law firm determine the best filing approach and the specifics of your claim.
  5. Your lawyer can file the claim for you and manage the process. This includes tasks such as discovery, negotiating a settlement or taking the case to court.

Finding the best representation for you can significantly impact your litigation experience. Your potential compensation from a settlement or verdict depends on the details of your case. Your lawyer will work to get you the maximum compensation possible.

Editor Lindsay Donaldson contributed to this article.

Please seek the advice of a qualified professional before making decisions about your health or finances.
Last Modified: March 4, 2025

24 Cited Research Articles

Consumernotice.org adheres to the highest ethical standards for content production and references only credible sources of information, including government reports, interviews with experts, highly regarded nonprofit organizations, peer-reviewed journals, court records and academic organizations. You can learn more about our dedication to relevance, accuracy and transparency by reading our editorial policy.

  1. United States Judicial Panel on Multidistrict Litigation. (2025, March 3). MDL Statistics Report - Distribution of Pending MDL Dockets by Actions Pending. Retrieved from https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-March-3-2025.pdf
  2. Brigham and Women’s Hospital. (2025). Non-Artertic Anterior Ischemic Optic Neuropathy (NAION). Retrieved from https://www.brighamandwomens.org/neurology/neuro-ophthalmology/non-arteritic-anterior-ischemic-optic-neuropathy
  3. National Library of Medicine. (2025). Ileus. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK558937/
  4. U.S. Food and Drug Administration. (2024, November 1). Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type
  5. U.S. District Court for the Eastern District of Pennsylvania. (2024, October 4). Teague v. Novo Nordisk; Complaint and Jury Demand, Civil Action No.: 2:24-Cv-5343. Retrieved from https://www.pacer.gov
  6. Hathaway, J.T. et al. (2024, July 3). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. Retrieved from https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255
  7. U.S. Judicial Panel on Multidistrict Litigation. (2024, February 2). Transfer Order, MDL No. 3094. Retrieved from https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3094-Transfer_Order-1-24.pdf
  8. U.S. District Court for the Eastern District of Pennsylvania. (2024). MDL 3094 in re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation. Retrieved from https://www.paed.uscourts.gov/mdl/mdl-3094-re-glucagon-peptide-1-receptor-agonists-glp-1-ras-products-liability-litigation
  9. U.S. District Court Western District of Louisiana Lake Charles Division. (2023, September 9). Complaint and Demand for Jury Trial. Retrieved from https://clg.org/pdf/2/6/8/1/Complaint-Louisiana.pdf
  10. Lynch, J., et al. (2023, August 3). Woman Sues Drug Makers of Ozempic and Mounjaro Over Severe Gastrointestinal Issues. Retrieved from https://www.cnn.com/2023/08/03/business/ozempic-mounjoro-lawsuit/index.html
  11. Moniuszko, S. (2023, August 3). Ozempic, Mounjaro Manufacturers Sued Over Claims of “Stomach Paralysis” Side Effects. Retrieved from https://www.cbsnews.com/news/ozempic-mounjaro-lawsuit-gastroparesis-stomach-paralysis-side-effect/
  12. U.S. District Court Western District of Louisiana Lake Charles Division. (2023, August 2). Complaint and Demand for Jury Trial. Retrieved from https://www.forthepeople.com/sites/default/files/2023-08/Morgan%20%26%20Morgan%20Ozempic%20Bjorklund%20complaint%208.2.23.pdf
  13. UCI Health. (2023, July 28). In-Demand Weight-Loss Drugs Are No Magic Bullet, UCI Health Experts Say. Retrieved from https://www.ucihealth.org/news/2023/07/ozempic-wegovy-caution
  14. Goodman, B. (2023, July 25). They Took Blockbuster Drugs for Weight Loss and Diabetes. Now Their Stomachs Are Paralyzed. Retrieved from https://www.cnn.com/2023/07/25/health/weight-loss-diabetes-drugs-gastroparesis/index.html
  15. Burger, L. et al. (2023, July 10). EU Investigates Ozempic, Weight-Loss Drug Saxenda After Suicidal Thoughts Reported. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/eu-probes-novos-weight-loss-drugs-reports-suicide-risks-bloomberg-news-2023-07-10/
  16. Roberts, M. (2023, July 9). Weight-Loss Jabs Investigated for Suicide Risk. Retrieved from https://www.bbc.com/news/health-66119059
  17. Cleveland Clinic. (2023, July 3). GLP-1 Agonists. Retrieved from https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
  18. Novo Nordisk. (2023, June 20). Press Release. Retrieved from https://www.novonordisk-us.com/media/news-archive/news-details.html?id=166121
  19. Ingram, D. (2023, June 15). More Than 4,000 Ads for Ozempic-Style Drugs Found Running on Instagram and Facebook. Retrieved from https://www.nbcnews.com/tech/internet/ozempic-weight-loss-drug-ads-instagram-wegovy-semaglutide-rcna88602
  20. He, L., et al. (2022, March 28). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8961394/
  21. U.S. Food and Drug Administration. (2022, March). Highlights of Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
  22. Kalas, M.A., et al. (2021, October 18). Medication-Induced Gastroparesis: A Case Report. Retrieved from https://journals.sagepub.com/doi/10.1177/23247096211051919
  23. U.S. Food and Drug Administration. (2019, September). Highlights of Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
  24. Morgan & Morgan. (n.d.). Morgan & Morgan Sues Ozempic® and Mounjaro™ Manufacturers. Retrieved from https://www.forthepeople.com/blog/morgan-morgan-sues-ozempicr-and-mounjarotm-manufacturers/